ENDRA Life Sciences NDRA recently announced positive findings from a clinical study assessing the measurement consistency of ...

In participants with highly active disease, the unadjusted annualized relapse rate (ARR) at Week 96 was 0.145 for BRIUMVI versus 0.496 for teriflunomide, representing a 70.8% relative reduction ...

A newly developed MRI-based scoring system may help identify patients at higher risk of early recurrence after surgical removal of small hepatocellular carcinoma (HCC). The findings, published in ...

Specialists call for early screening for better prevention and early treatment By Kumudini Hettiarachchi The largest solid ...

For many, especially women, these scans are compelling. They offer agency in a healthcare system that often feels slow, ...

Psychologically, it's really hard knowing that we aren’t doing anything to stop the cancer growing.

FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...

Roche announces FENhance 1 phase III study of fenebrutinib for relapsing and primary progressive MS meets its primary endpoint: Basel Wednesday, March 4, 2026, 14:00 Hrs [IST] Roc ...

FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...

TD Cowen 46th Annual Health Care Conference March 2, 2026 3:10 PM ESTCompany ParticipantsSanjiv Patel - CEO, President ...

Good morning, everybody. My name is Kyahn Williamson, SVP of Investor Relations and Corporate Communications at Telix. And we're very pleased to welcome you today to our investor call and webcast to ...